Luvometinib in Combination With Serplulimab for NF2-Related Tumors

NCT07708285 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

NF2-related Schwannomatosis
NF2
Neurofibromatosis Type 2
Vestibular Schwannoma
Meningioma

Interventions

DRUG: Luvometinib
DRUG: Serplulimab

Sponsor

Beijing Tiantan Hospital